NCT03418922 - A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

December 28, 2022

Study Completion Date

December 28, 2022

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Lenvatinib

Specified doses will be administered orally on specified days.

DRUG

Nivolumab

Specified doses will be administered intravenously on specified days.

Trial Locations (6)

Eisai Trial Site 1, Kashiwa

Eisai Trial Site 6, Iizuka

Eisai Trial Site 3, Kawasaki

Eisai Trial Site 4, Sayama

Eisai Trial Site 2, Chuo-ku

Eisai Trial Site 5, Chiba